Literature DB >> 30267504

Epstein-barr virus-associated encephalitis in a case-series of more than 40 patients.

Pavel Dyachenko1, Olha Smiianova2, Victoria Kurhanskaya2, Alexander Oleshko2, Anatoly Dyachenko2.   

Abstract

OBJECTIVE: Introduction: Epstein-Barr virus (EBV) infection can present with neurologic manifestations including encephalitis, aseptic meningitis, Guillain-Barre syndrome, and many others. Most reported cases have been in children. Little is known about EBV encephalitis in adults. The aim: To describe the clinical presentations, investigational findings, management and outcome of adult patients with EBV encephalitis. PATIENTS AND METHODS: Materials and methods: This report conducted a retrospective review of all cases of EBV-associated encephalitis compiled in the Kyiv's referral hospital from January 2016 to December 2017.
RESULTS: Review: Out of 226 adult patients hospitalized with acute encephalitis during the study period, 48 (21.2%) were identified as having evidence of EBV-infection: convincing EBV serology and/or positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR) in patients that had no bacterial cause of encephalitis. EBV monoinfection was registered in 24 (50%) patients. Mixed herpesvirus infection with one to four viruses in addition to EBV was detected in the rest. The most common symptoms were fever, confusion, headache, focal neurological deficits, vestibulo-ataxic disorders. CSF cytosis, content of protein and glucose were close to normal. Magnetic resonance imaging (MRI) showed focal (28/58.3%) and diffuse (15/31.3%) changes of the brain parenchymal. All patients got antiviral medication: ganciclovir, valganciclovir or valaciclovir, as a rule. Outcome: 26 (54%) patients recovered without any disabling sequela, 21 (44%) patients with remaining preservations were transferred to a convalescence facility. One patient, which condition worsened against the background of the therapy, were moved to an intensive care unit. No patient died.
CONCLUSION: Conclusions: CNS infection with EBV only and as a mixed infection is common in Ukraine. Presentation of EBV-infection is non-specific, both as MR imaging, sometimes reminding of HSV-1 infection. Prognosis of the disease is favorable.

Entities:  

Keywords:  encephalitis ; Epstein-Barr virus

Mesh:

Year:  2018        PMID: 30267504

Source DB:  PubMed          Journal:  Wiad Lek        ISSN: 0043-5147


  6 in total

1.  Clinical characteristics of Epstein-Barr virus infection in the pediatric nervous system.

Authors:  Huan Cheng; Doudou Chen; Xiaoling Peng; Peng Wu; Li Jiang; Yue Hu
Journal:  BMC Infect Dis       Date:  2020-11-25       Impact factor: 3.090

2.  Epstein-Barr Virus Encephalitis and Disseminated Adenovirus Infection after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for a Patient with Ph-Like Acute Lymphoblastic Leukemia.

Authors:  Xiao Zhou; Xianmin Song; Liping Wan
Journal:  Case Rep Oncol       Date:  2022-03-14

Review 3.  Etiology, Clinical Phenotypes, Epidemiological Correlates, Laboratory Biomarkers and Diagnostic Challenges of Pediatric Viral Meningitis: Descriptive Review.

Authors:  Saleh M Al-Qahtani; Ayed A Shati; Youssef A Alqahtani; Abdelwahid Saeed Ali
Journal:  Front Pediatr       Date:  2022-06-16       Impact factor: 3.569

Review 4.  Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review.

Authors:  Zheng Li; Xingye Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Environ Sci Pollut Res Int       Date:  2021-03-06       Impact factor: 4.223

Review 5.  The spectrum of Epstein-Barr virus infections of the central nervous system after organ transplantation.

Authors:  Mohamed Ridha; Dylan G Jones; David P Lerner; Michal Vytopil; Barbara Voetsch; Joseph D Burns; Anil Ramineni; Pooja Raibagkar
Journal:  Virol J       Date:  2021-08-06       Impact factor: 4.099

6.  Comparison of clinical characteristics of a patient with Epstein-Barr virus-associated seizure and patients with COVID-19-associated seizure.

Authors:  Larry Nichols; Merritt Thompson; Gretchen L Bentz
Journal:  J Med Virol       Date:  2021-07-20       Impact factor: 20.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.